May 21, 2007
WEST SACRAMENTO, Calif., May 21, 2007 - Lipomics Technologies, Inc., a privately held
company that specializes in the analysis of lipid metabolites, announced today that they have
entered into a two year collaborative research agreement with Duke University in several key
clinical areas to identify pharmacometabolomic markers. Lipomics will provide Duke analytical
services for biomarker discovery and validation (using its proprietary platform and technologies
relating to lipid profiles) as well as provide data transfer and interpretation services that will
streamline the process of biomarker development allowing researchers at Duke easy access to
analysis and data. In return, Lipomics will receive an option to license diagnostic rights on all such
markers developed under this agreement through use of Lipomics proprietary technologies. Initial
clinical areas are CNS (schizophrenia and depression) and Cardiovascular (response to statins)
disorders.
Results from the first project of the collaboration were presented at the Society of Biological
Psychiatry meeting in San Diego on May 18th, 2007. The study aimed to define metabolic
signatures for patients treated with anti-psychotic drugs.
“We are very excited about this partnership. It is a great honor to work with Duke University, one
of the leading academic institutions in the country, to advance our clinical diagnostic program”
said Dr. Meeta Patnaik, chief medical officer, Lipomics.
Financial terms of the collaboration were not disclosed.